Detection Of Braf Mutation In The Cytocentrifugation Supernatant Fluid From Fine-Needle Aspiration Of Thyroid Lesions May Enhance The Diagnostic Yield

Keywords

BRAF; fine-needle aspirate; fine-needle aspiration supernatant; papillary thyroid carcinoma

Abstract

Objective: BRAF mutations using cellular DNA from fine-needle aspiration (FNA) specimens are commonly used to support the diagnosis of papillary thyroid carcinoma (PTC). The goal of this study was to preliminarily evaluate the diagnostic utility of detecting BRAF mutations in the routinely discarded FNA specimen supernatant fluid. Materials and Methods: Seventy-eight FNAs of thyroid lesions were evaluated for BRAF mutations using both cellular and supernatant DNA. BRAF mutation data were correlated with cytology and surgical pathology. Results: Of the 78 samples evaluated, 68 (87%) had amplifiable DNA in the supernatant with 2 (3%) positive for BRAF mutations. These two samples showed no mutations in the cellular counterpart. Among the 11 samples showing morphologic findings (FNA/surgical pathology) suspicious/diagnostic of PTC, 6 (55%) samples (one supernatant and five cellulars) were positive for BRAF mutations. This suggests that testing supernatant DNA in FNA specimens may increase the diagnostic yield by 1/11 (9%) in this setting. Conclusions: The vast majority of routinely discarded FNA supernatants contain amplifiable DNA. In addition, profiling the mutations of BRAF and other genes using supernatant DNA may provide valuable diagnostic information to assist the diagnosis of PTC in patients with clinical/morphologic findings suspicious for malignancies and cellular DNA showing no mutations.

Publication Date

1-1-2017

Publication Title

CytoJournal

Volume

14

Issue

1

Document Type

Article

Personal Identifier

scopus

DOI Link

https://doi.org/10.4103/1742-6413.200935

Socpus ID

85018503449 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/85018503449

This document is currently not available here.

Share

COinS